<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03980769</url>
  </required_header>
  <id_info>
    <org_study_id>RG1005072</org_study_id>
    <secondary_id>NCI-2019-03243</secondary_id>
    <secondary_id>9621</secondary_id>
    <secondary_id>P30CA015704</secondary_id>
    <nct_id>NCT03980769</nct_id>
  </id_info>
  <brief_title>Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Thiotepa in Treating Patients With Non-malignant Disorders</brief_title>
  <official_title>Allogeneic Hematopoietic Cell Transplantation for Patients With Non-Malignant Disorders Using Treosulfan, Fludarabine, and Thiotepa</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fred Hutchinson Cancer Research Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Fred Hutchinson Cancer Research Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase II trial studies how well donor stem cell transplant, treosulfan, fludarabine, and
      thiotepa work in treating patients with non-cancerous disorders. Giving chemotherapy before a
      donor transplant helps stop the growth of cells in the bone marrow, including normal
      blood-forming cells (stem cells) and cancer cells. It may also stop the patient's immune
      system from rejecting the donor's stem cells. When the healthy stem cells from a donor are
      infused into the patient they may help the patient's bone marrow make stem cells, red blood
      cells, white blood cells, and platelets. The donated stem cells may also replace the
      patient's immune cells and help destroy any remaining cancer cells.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients receive thiotepa intravenously (IV) twice daily (BID) on days -7, treosulfan IV on
      days -6 to -4, fludarabine IV on days -6 to -2, and rabbit anti-thymocyte globulin IV on days
      -4 to -2. Patients then undergo allogeneic hematopoietic cell transplant via infusion on day
      0.

      After completion of study treatment, patients are followed up at 1 year and then annually
      thereafter.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 1, 2020</start_date>
  <completion_date type="Anticipated">July 1, 2027</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2027</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Engraftment failure</measure>
    <time_frame>1 year after transplant</time_frame>
    <description>Will be defined as donor CD3 chimerism &lt; 5% at 1 year after transplant.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Treatment related mortality</measure>
    <time_frame>At 100 and 200 days</time_frame>
    <description>Will be defined as any death not attributable to the underlying disease.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Allogeneic Hematopoietic Stem Cell Transplantation Recipient</condition>
  <condition>Benign Neoplasm</condition>
  <condition>Donor</condition>
  <arm_group>
    <arm_group_label>Treatment (chemotherapy, transplant)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive thiotepa IV BID on days -7, treosulfan IV on days -6 to -4, fludarabine IV on days -6 to -2, and rabbit anti-thymocyte globulin IV on days -4 to -2. Patients then undergo allogeneic hematopoietic cell transplant via infusion on day 0.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Thiotepa</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (chemotherapy, transplant)</arm_group_label>
    <other_name>1,1',1&quot;-phosphinothioylidynetrisaziridine</other_name>
    <other_name>N,N', N''-Triethylenethiophosphoramid</other_name>
    <other_name>Oncotiotepa</other_name>
    <other_name>STEPA</other_name>
    <other_name>Tepadina</other_name>
    <other_name>TESPA</other_name>
    <other_name>Tespamin</other_name>
    <other_name>Tespamine</other_name>
    <other_name>Thio-Tepa</other_name>
    <other_name>Thiofosfamide</other_name>
    <other_name>Thiofozil</other_name>
    <other_name>Thiophosphamide</other_name>
    <other_name>Thiophosphoramide</other_name>
    <other_name>Thiotef</other_name>
    <other_name>Tifosyl</other_name>
    <other_name>TIO TEF</other_name>
    <other_name>Triethylene thiophosphoramide</other_name>
    <other_name>Triethylenethiophosphoramide</other_name>
    <other_name>TSPA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Treosulfan</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (chemotherapy, transplant)</arm_group_label>
    <other_name>(S-(R*,R*))-1,2,3,4-butanetetrol</other_name>
    <other_name>1,4-dimethanesulfonate</other_name>
    <other_name>[R-(R*,S*)]-, 299-75-2, 39069</other_name>
    <other_name>Dihydroxybusulfan</other_name>
    <other_name>Ovastat</other_name>
    <other_name>Treosulphan</other_name>
    <other_name>Tresulfon</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (chemotherapy, transplant)</arm_group_label>
    <other_name>Given IV</other_name>
    <other_name>118218</other_name>
    <other_name>2-Fluoro-9-beta-arabinofuranosyladenine</other_name>
    <other_name>2-Fluorovidarabine</other_name>
    <other_name>21679-14-1</other_name>
    <other_name>9-Beta-D-arabinofuranosyl-2-fluoroadenine</other_name>
    <other_name>Fluradosa</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine Phosphate</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (chemotherapy, transplant)</arm_group_label>
    <other_name>2-F-ara-AMP</other_name>
    <other_name>312887</other_name>
    <other_name>328002</other_name>
    <other_name>75607-67-9</other_name>
    <other_name>9H-Purin-6-amine</other_name>
    <other_name>2-fluoro-9-(5-O-phosphono-.beta.-D-arabinofuranosyl)-</other_name>
    <other_name>Beneflur</other_name>
    <other_name>Fludara</other_name>
    <other_name>Fludarabine-5'-Monophosphate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Rabbit Anti-Thymocyte Globulin</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (chemotherapy, transplant)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Allogeneic Hematopoietic Stem Cell Transplantation</intervention_name>
    <description>Undergo HCT via infusion</description>
    <arm_group_label>Treatment (chemotherapy, transplant)</arm_group_label>
    <other_name>Allogeneic Hematopoietic Cell Transplantation</other_name>
    <other_name>Allogeneic Stem Cell Transplantation</other_name>
    <other_name>HSC</other_name>
    <other_name>HSCT</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient with nonmalignant disease treatable by allogenic HCT

          -  Patient with a known nonmalignant disease that is not clearly defined, if discussed
             with protocol principal investigator (PI) (Dr. Lauri Burroughs) to determine if they
             are eligible for HCT on the study

          -  DONOR: For the very few occasions where we identify a donor hematopoietic progenitor
             cell (HPC)-A from a non-NMDP source, we have procedures in place through our unrelated
             donor office to collect the information necessary to comply with donor testing,
             screening, and declaration of donor eligibility according to 21 CFR 1271. We require
             that the donor testing be performed by a United States Clinical Laboratory Improvement
             Amendment (CLIA) approved laboratory. In the very rare case where the donor testing is
             not able to be performed in a CLIA-approved laboratory, or there is confirmatory
             testing that needs to be performed, or for any donor identified from Europe and at
             risk for Creutzfeldt-Jakob disease (CJD), we note this on the donor screening form and
             require that the unrelated donor medical director or the attending physician approves
             the use of the donor HPC-A product under urgent medical need

          -  DONOR: Human leukocyte antigen (HLA)-identical related donor OR unrelated donor
             matched for HLA-A, B, C, DRB1 and DQB1 or mismatched for a single allele at HLA-A, B,
             C, or a single DQB1 antigen or allele mismatch by high resolution deoxyribonucleic
             acid (DNA) typing

          -  DONOR: Bone marrow is the preferred cell source (when feasible). However, PBSC is also
             allowed and the PI may determine if PBSC is preferred for certain patients

          -  DONOR: HLA-matched sibling bone marrow in combination with HLA-matched sibling
             umbilical cord blood if the HLA-matched sibling umbilical cord blood was collected and
             stored. The HLA-matched sibling bone marrow and cord blood would be matched for HLA-A,
             B, C, DRB1 and DQB1

        Exclusion Criteria:

          -  Patients with idiopathic aplastic anemia and Fanconi anemia; patients with aplastic
             anemia associated with paroxysmal nocturnal hemoglobinuria (PNH) or inherited marrow
             failure syndromes (except Fanconi anemia) will be allowed

          -  Impaired cardiac function as evidenced by ejection fraction &lt; 35% (or, if unable to
             obtain ejection fraction, shortening fraction of &lt; 26%) or cardiac insufficiency
             requiring treatment or symptomatic coronary artery disease. Patients with a shortening
             fraction of &lt; 26% may be enrolled if approved by a cardiologist

          -  Impaired pulmonary function as evidenced by carbon monoxide diffusing capability
             (DLCO) &lt; 50% of predicted (or, if unable to perform pulmonary function tests, then
             oxygen [O2] saturation &lt; 92% on room air)

          -  Impaired renal function as evidenced by creatinine-clearance &lt; 50% for age, weight,
             height or serum creatinine &gt; 2 X upper normal limit or dialysis-dependent

          -  Evidence of synthetic dysfunction or severe cirrhosis requiring deferral of
             conditioning as recommended by a gastroenterology specialist

          -  Active infectious disease requiring deferral of conditioning as recommended by an
             infectious disease specialist

          -  Positive for HIV (human immunodeficiency virus)

          -  Females who are pregnant or breast-feeding

          -  Known hypersensitivity to treosulfan, fludarabine, and/or thiotepa

          -  DONOR: Donors deemed unable to undergo marrow harvesting of PBSC mobilization and
             leukapheresis

          -  DONOR: HIV-positive donors

          -  DONOR: Donors with active infectious hepatitis

          -  DONOR: Female donor with positive pregnancy test

          -  DONOR: Donors are excluded if the patient has an identified antibody against a
             donor-specific HLA locus as specified in standard practice

          -  DONOR: HLA-matched sibling cord blood units that have not passed donor screening for
             infectious disease markers as recommended by the National Marrow Donor Project (NMDP)
             will not be used unless a waiver is signed by the clinical attending allowing use of
             cord blood unit. Cord blood units are presumed to be cytomegalovirus (CMV) negative
             regardless of serologic testing due to passive transmission of maternal CMV antibodies
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>49 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lauri Burroughs</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fred Hutch/University of Washington Cancer Consortium</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lauri Burroughs</last_name>
    <phone>206-667-2396</phone>
    <email>lburroug@fredhutch.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Fred Hutch/University of Washington Cancer Consortium</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Lauri Burroughs</last_name>
      <phone>206-667-2396</phone>
      <email>lburroug@fredhutch.org</email>
    </contact>
    <investigator>
      <last_name>Lauri Burroughs</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Froedtert and the Medical College of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Julie-An Talano</last_name>
      <phone>414-456-4170</phone>
    </contact>
    <investigator>
      <last_name>Julie-An Talano</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>June 6, 2019</study_first_submitted>
  <study_first_submitted_qc>June 6, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 10, 2019</study_first_posted>
  <last_update_submitted>July 1, 2020</last_update_submitted>
  <last_update_submitted_qc>July 1, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vidarabine</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Thiotepa</mesh_term>
    <mesh_term>Treosulfan</mesh_term>
    <mesh_term>Busulfan</mesh_term>
    <mesh_term>Antilymphocyte Serum</mesh_term>
    <mesh_term>Thymoglobulin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

